Stockreport

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model [Yahoo! Finance]

Skye Bioscience, Inc.  (SKYE) 
PDF New in vitro data demonstrates superior potency of nimacimab's differentiated and favorable mechanism of inhibition versus monlunabant Nimacimab Phase 2a CBeyond™ top [Read more]